A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Clinical trial NCT06833073 · RECRUITING

Trial details

NCT number: NCT06833073
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urinary Bladder Neoplasms Non-Muscle Invasive Bladder Neoplasms Carcinoma in Situ

Start date: 2025-03-11
Primary completion: 2031-09-03
Enrollment: 308

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.